APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Saved in:
| Title: | APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. |
|---|---|
| Authors: | Natesan D; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Zhang L; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Martell HJ; Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA, United States., Jindal T; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Devine P; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Stohr B; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Espinosa-Mendez C; Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA, United States., Grenert J; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Van Ziffle J; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Joseph N; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Umetsu S; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Onodera C; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Turski M; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Chan E; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Desai A; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Aggarwal R; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Wong A; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Porten S; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Chou J; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Friedlander T; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Fong L; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Small EJ; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States., Sweet-Cordero A; Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA, United States., Koshkin VS; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2022 Mar 07; Vol. 12, pp. 816706. Date of Electronic Publication: 2022 Mar 07 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
